Right now, all the focus is on psilocybin for treatment-resistant depression—that's severe depression that doesn't respond to normal antidepressants. But new trial data suggests psilocybin might also work for regular depression that hasn't been treated yet. An Investigational New Drug (IND) application is the FDA's permission slip for a drug company to start human trials. This prediction says that before the end of 2026, at least one company will get FDA permission to test psilocybin on regular depression patients, not just the most severe cases.
Emerging trial data suggesting psilocybin efficacy in earlier-line MDD patients (not limited to TRD) represents a genuine paradigm shift in indication scope. IND applications are low-barrier regulatory steps; Australia's expanded prescriber framework and recent fundraising (Psilera $8.8M) confirm clinical translation momentum. Falsifiable: requires an actual FDA IND grant letter for a non-TRD MDD indication by December 31, 2026. Confidence discounted because IND grants are not always publicly announced promptly.